Who
Christopher John Kenney
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Xenon Pharmaceuticals.
In numbers
- Trades disclosed
- 30
- Buys
- 1
- Sells
- 4
- Bought
- $20K
- Sold
- $1.4M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Aug 2021
- Last trade
- 28 Aug 2026
- Last filed
- 31 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Aug 2026filed 31 Aug 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $383K6,368 at $60.17 | filing |
| 28 Aug 2026filed 31 Aug 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K700 at $60.98 | filing |
| 28 Aug 2026filed 31 Aug 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $383K6,368 at $60.17 | filing |
| 28 Aug 2026filed 31 Aug 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $43K700 at $60.98 | filing |
| 13 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $78K1,410 at $55.23 | filing |
| 13 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $78K1,410 at $55.23 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,750 at $0.00 | filing |
| 12 Mar 2026filed 13 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —3,750 | filing |
| 10 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $167K2,771 at $60.11 | filing |
| 10 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $167K2,771 at $60.11 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —7,500 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —7,500 at $0.00 | filing |
| 9 Mar 2026filed 11 Mar 2026 | XENE Xenon PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —7,500 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 9 Jan 2026filed 9 Jan 2026 | XENE Xenon Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
News
Contrasting Xenon Pharmaceuticals (NASDAQ:XENE) and United Therapeutics (NASDAQ:UTHR)XENE · dailypolitical.com · 18 Oct 2026Head to Head Survey: Xenon Pharmaceuticals (NASDAQ:XENE) vs. United Therapeutics (NASDAQ:UTHR)XENE · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Christopher John Kenney; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.